Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

Lorraine Tafra, Zandra Cheng, Joseph Uddo, Mary B. Lobrano, William Stein, Wendie A. Berg, Edward Levine, Irving N. Weinberg, Deepa Narayanan, Eric Ross, David Beylin, Stephen Yarnall, Rochelle Keen, Kristen Sawyer, Jack Van Geffen, Rita L. Freimanis, Edward Staab, Lee P. Adler, Judy Lovelace, Perry ShenJohn Stewart, Sergei Dolinsky

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

Original languageEnglish (US)
Pages (from-to)628-632
Number of pages5
JournalAmerican journal of surgery
Volume190
Issue number4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Keywords

  • 18F-fluorodeoxyglucose
  • Breast cancer
  • Positron-emission tomography

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer'. Together they form a unique fingerprint.

Cite this